Use of Anabolic-Androgenic Steroids and Male Fertility: A Systematic Review and Meta-analysis

Author:

Mulawkar Prashant Motiram123,Maheshwari Pankaj N.4,Gauhar Vineet5,Agrawal Sumeet Gopal6,Mohammed Taofiq Olayinka7,Singh Abhishek Gajendra8,Tak Gopal Ramdas9,Shah Utsav Shailesh10,Shukla Deepali Parthsarthi11,Mamankar Deepali12

Affiliation:

1. Urology, Tirthankar Superspeciality Hospital, Mumbai, India

2. Department of Urology, GMC and SSH, Mumbai, India

3. Urology, University of Edinburgh, Edinburgh, UK

4. Fortis Hospital Mulund, Mumbai, India

5. Urology, Ng Teng Fong General Hospital, NUHS, Singapore

6. Urology, Lotus Superspeciality Hospital, Maharashtra, India

7. Urology, University of Ilorin Teaching Hospital, Ilorin, Nigeria

8. Urology, MPUH, Nadiad, India

9. Urology, Asian Institute of Nephrology and Urology, Hyderabad, Telangana, India

10. Urology, Bodyline Hospitals, Ahmedabad, Gujarat, India

11. Shukla Test Tube Baby Centre, Maharashtra, India

12. Amardeep IVF and Fertility Centre, Akola, Maharashtra, India

Abstract

Abstract Background: Anabolic-androgenic steroids (AASs) are often used by men for bodybuilding and to improve sports performance. The use is not limited to professional competitive athletes, but many amateur men. Objective: The objective of this study was to assess and systematically review the effects of AAS on male fertility parameters, spermiogram, testosterone, follicle-stimulating hormone (FSH) and luteinising hormone (LH) and to review reversibility and other morbidity impacting fertility. Methods: Eligibility criteria - We included studies mentioning data about adult males using supraphysiologic doses of AAS for sports performance or appearance enhancement, with comparison data from general population or matched controls if available reporting fertility parameters and sexual performance. Information sources - A systematic literature search was performed using PubMed, MEDLINE, EMBASE, Google Scholar and World of Science. Controlled clinical trials randomised or nonrandomised (if available), case series with or without matched controls, case reports, cross-sectional surveys, reports on follow-up of subjects caught in doping test and their fertility parameters when reported. Risk of bias/quality assessment - The quality assessment of the included studies was performed using the Newcastle–Ottawa Scale. Results: Included studies - Thirty-two studies were included. There were 12 cohort studies, 5 case–control studies, 9 cross-sectional surveys and 6 case reports. The study population comprised 9371 individuals, of which 2671 were AAS users. Synthesis of results - AAS users had reduced levels of FSH and LH than the naïve population. These levels remained low for 3–6 months after stopping AAS. One year after stopping AAS, the users and naïve population had insignificant differences in FSH and LH values. The total testosterone (TT) levels were comparable in users and naïve populations at baseline, 3 months and 6 months after stopping, but at 1 year, TT values were lower in AAS users. Sperm concentration in AAS users and naïve population was similar, but sperm motility was lower in AAS users. The testicular size was lower in AAS users. The erectile function improved with AAS use, but on withdrawal, there was decreased libido and erectile dysfunction. Most AAS users need additional medications to mitigate detrimental effects on fertility. Description of the effect - AAS use negatively impacted the gonadotrophin levels and had lower sperm motility and testicular size. Strength - Comprehensive review of 32 publications, study population of 9371 individuals, of which 2671 were AAS users, meta-analysis of reproductive hormones, semen parameters and testis size. Limitations: The limitations are small sample size of most of the studies, polypharmacy, lack of information on dosing and high heterogeneity. Interpretation: AAS use is detrimental for sperm motility and has a partially reversible negative impact on male fertility. Users must be cautioned about its negative impact on libido and erectile function. Registration: PROSPERO Registration No. CRD42023411294.

Publisher

Medknow

Subject

Reproductive Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3